Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

• 3 mid-caps nether $20 that Wall Street loves

Ardelyx (NASDAQ:ARDX) executives said astatine the Jefferies Global Healthcare Conference that the institution is focused connected expanding request for its commercialized products, IBSRELA and XPHOZAH, portion continuing to put successful its pipeline and positioning the concern for sustainable profitability.

Chief Financial Officer Sue Hohenleitner said Ardelyx expects its 2 commercialized products to make much than $500 cardinal successful top-line gross this year. IBSRELA, the company’s attraction for irritable bowel syndrome with constipation, oregon IBS-C, represents the largest information of that outlook, with guidance of $410 cardinal to $430 million. XPHOZAH, utilized for patients connected dialysis with hyperphosphatemia, is expected to lend $110 cardinal to $120 million.

→ Palantir’s Drone Tailwind Puts Its Defense AI Story Back successful Focus for Investors

• Is Ardelyx is A Buy After Slip successful Early 2022

Hohenleitner outlined 4 strategical priorities: expanding IBSRELA demand, sustaining XPHOZAH momentum, advancing the company’s pipeline and maintaining beardown fiscal performance, including top-line maturation and a steadfast currency position.

IBSRELA Remains Ardelyx’s Main Growth Driver

Chief Commercial Officer Eric Foster said IBSRELA is positioned arsenic an enactment for IBS-C patients who request thing antithetic aft attraction with GC-C agonists specified arsenic LINZESS oregon Trulance. He said Ardelyx probe indicates that astir 77% of patients proceed to person symptoms oregon are not satisfied connected a GC-C agonist.

→ Best Buy’s AI Laptop Boost Sparks Hope for a BBY Turnaround

Foster said IBSRELA benefits from a unsocial mechanics of enactment arsenic an NHE3 inhibitor, on with objective efficacy and information data. Ardelyx is targeting astir 14,000 wellness attraction providers, including high-prescribing gastroenterologists, superior attraction physicians and precocious signifier providers, who correspond astir fractional of the full medicine marketplace the institution is focused on.

Foster said IBSRELA grew 73% twelvemonth implicit twelvemonth successful 2025 and 58% twelvemonth implicit twelvemonth successful the archetypal 4th compared with the prior-year period. He attributed the maturation to respective factors, including a larger income force, much targeted doc engagement, improved medicine fulfillment done the IBSRELA Pharmacy Network and diligent activation efforts.

→ 3 Up-and-Coming Stocks That Could Be the Next NVIDIA

The institution doubled the size of its IBSRELA income unit successful precocious 2024 and is adding astir 20 representatives, bringing the full to 144. Foster said the caller representatives are expected to beryllium successful the tract by July 1. Ardelyx is besides adding tract reimbursement managers to assistance physicians navigate payer requirements.